EZH2 inhibitor GSK343 inhibits sepsis‑induced intestinal disorders

Yue,Dongyou; Wang,Zhiying; Yang,Yongan; Hu,Zhenjun; Luo,Ganping; Wang,Fu

doi:10.3892/etm.2021.9854

EZH2 inhibitor GSK343 inhibits sepsis‑induced intestinal disorders

Authors:
- Dongyou Yue
- Zhiying Wang
- Yongan Yang
- Zhenjun Hu
- Ganping Luo
- Fu Wang
View Affiliations

Affiliations: Department of Emergency, The First People's Hospital of Chenzhou City, Chenzhou, Hunan 423000, P.R. China, Department of Neurology, The First People's Hospital of Chenzhou City, Chenzhou, Hunan 423000, P.R. China, Department of Critical Care Medicine, Zhangye Second People's Hospital, Zhangye, Gansu 734000, P.R. China
Published online on: February 26, 2021 https://doi.org/10.3892/etm.2021.9854
Article Number: 437
Copyright: © Yue et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Enhancer of zeste homolog 2 (EZH2) is positively associated with poor clinical outcomes in a number of aggressive tumors. Recent studies have demonstrated that inhibition of EZH2 also suppressed the inflammatory response during sepsis. The present study aimed to investigate whether an inhibitor of EZH2, GSK343, could protect the intestine against sepsis‑induced injury in vivo. Mice underwent cecal ligation and perforation (CLP) to induce sepsis and were assigned into three groups: Sham, CLP and CLP + GSK343. For GSK343 treatment, the septic mice were intravenously injected with GSK343 at 6 h post‑CLP. The results indicated that EZH2 was highly expressed while tight junction (TJ) proteins ZO‑1, occludin and claudin‑1 expression was reduced in the intestinal tissue of mice subjected to CLP compared with the sham group. CLP operation also caused intestinal pathological injury and the production of inflammatory cytokines including TNF‑α, IL‑1β and IL‑6 in both serum and intestinal tissues. Meanwhile, CLP induced cell apoptosis of intestinal tissue based on the increased number of apoptotic cells, reduced expression of Bcl‑2 and higher expression of caspase‑3 and Bax. However, the presence of GSK343 partially rescued intestinal pathological injury, reduced the level of inflammatory cytokines, repressed cell apoptosis and promoted TJ protein expression. Finally, the decreased number of Paneth cells caused by CLP operation was reversed by GSK343 treatment. In conclusion, the results of the present study demonstrated that GSK343 could protect the intestine against sepsis‑induced injury in vivo. Inhibition of EZH2 may provide a therapeutic approach for intestinal dysfunction during sepsis.

View Figures

View References

1	Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Turnbull IR and Vincent JL: Sepsis and septic shock. Nat Rev Dis Primers. 2(16045)2016.PubMed/NCBI View Article : Google Scholar
2	Fleischmann C, Scherag A, Adhikari NK, Hartog CS, Tsaganos T, Schlattmann P, Angus DC and Reinhart K: International Forum of Acute Care Trialists. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med. 193:259–272. 2016.PubMed/NCBI View Article : Google Scholar
3	Rello J, Valenzuela-Sánchez F, Ruiz-Rodriguez M and Moyano S: Sepsis: A review of advances in management. Adv Ther. 34:2393–2411. 2017.PubMed/NCBI View Article : Google Scholar
4	Lelubre C and Vincent JL: Mechanisms and treatment of organ failure in sepsis. Nat Rev Nephrol. 14:417–427. 2018.PubMed/NCBI View Article : Google Scholar
5	Mowat AM and Agace WW: Regional specialization within the intestinal immune system. Nat Rev Immunol. 14:667–685. 2014.PubMed/NCBI View Article : Google Scholar
6	Brown EM, Sadarangani M and Finlay BB: The role of the immune system in governing host-microbe interactions in the intestine. Nat Immunol. 14:660–667. 2013.PubMed/NCBI View Article : Google Scholar
7	Fay KT, Ford ML and Coopersmith CM: The intestinal microenvironment in sepsis. Biochim Biophys Acta Mol Basis Dis. 1863:2574–2583. 2017.PubMed/NCBI View Article : Google Scholar
8	Hwang JS, Kim KH, Park J, Kim SM, Cho H, Lee Y and Han IO: Glucosamine improves survival in a mouse model of sepsis and attenuates sepsis-induced lung injury and inflammation. J Biol Chem. 294:608–622. 2019.PubMed/NCBI View Article : Google Scholar
9	Hu Q, Ren H, Li G, Wang D, Zhou Q, Wu J, Zheng J, Huang J, Slade DA, Wu X and Ren J: STING-mediated intestinal barrier dysfunction contributes to lethal sepsis. EBioMedicine. 41:497–508. 2019.PubMed/NCBI View Article : Google Scholar
10	Zhou Q and Verne GN: Intestinal hyperpermeability: A gateway to multi-organ failure? J Clin Invest. 128:4764–4766. 2018.PubMed/NCBI View Article : Google Scholar
11	Tremblay-LeMay R, Rastgoo N, Pourabdollah M and Chang H: EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies. Biomark Res. 6(34)2018.PubMed/NCBI View Article : Google Scholar
12	Margueron R and Reinberg D: The Polycomb complex PRC2 and its mark in life. Nature. 469:343–349. 2011.PubMed/NCBI View Article : Google Scholar
13	Gan L, Yang Y, Li Q, Feng Y, Liu T and Guo W: Epigenetic regulation of cancer progression by EZH2: From biological insights to therapeutic potential. Biomark Res. 6(10)2018.PubMed/NCBI View Article : Google Scholar
14	Zhang Q, Sun H, Zhuang S, Liu N, Bao X, Liu X, Ren H, Lv D, Li Z, Bai J, et al: Novel pharmacological inhibition of EZH2 attenuates septic shock by altering innate inflammatory responses to sepsis. Int Immunopharmacol. 76(105899)2019.PubMed/NCBI View Article : Google Scholar
15	Cazorla SI, Maldonado-Galdeano C, Weill R, De Paula J and Perdigón GD: Oral administration of probiotics increases paneth cells and intestinal antimicrobial activity. Front Microbiol. 9(736)2018.PubMed/NCBI View Article : Google Scholar
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
17	Chen S, He Y, Hu Z, Lu S, Yin X, Ma X, Lv C and Jin G: Heparanase mediates intestinal inflammation and injury in a mouse model of sepsis. J Histochem Cytochem. 65:241–249. 2017.PubMed/NCBI View Article : Google Scholar
18	Dokladny K, Zuhl MN and Moseley PL: Intestinal epithelial barrier function and tight junction proteins with heat and exercise. J Appl Physiol (1985). 120:692–701. 2016.PubMed/NCBI View Article : Google Scholar
19	Günzel D and Fromm M: Claudins and other tight junction proteins. Compr Physiol. 2:1819–1852. 2012.PubMed/NCBI View Article : Google Scholar
20	Zeisel MB, Dhawan P and Baumert TF: Tight junction proteins in gastrointestinal and liver disease. Gut. 68:547–561. 2019.PubMed/NCBI View Article : Google Scholar
21	Clevers HC and Bevins CL: Paneth cells: Maestros of the small intestinal crypts. Annu Rev Physiol. 75:289–311. 2013.PubMed/NCBI View Article : Google Scholar
22	Schmitt M, Schewe M, Sacchetti A, Feijtel D, van de Geer WS, Teeuwssen M, Sleddens HF, Joosten R, van Royen ME, van de Werken HJ, et al: Paneth cells respond to inflammation and contribute to tissue regeneration by acquiring stem-like features through SCF/c-Kit signaling. Cell Rep. 24:2312–2328.e2317. 2018.PubMed/NCBI View Article : Google Scholar
23	Holly MK and Smith JG: Paneth cells during viral infection and pathogenesis. Viruses. 10(225)2018.PubMed/NCBI View Article : Google Scholar
24	Han SJ, Kim M, D'Agati VD and Lee HT: Norepinephrine released by intestinal Paneth cells exacerbates ischemic AKI. Am J Physiol Renal Physiol. 318:F260–F272. 2020.PubMed/NCBI View Article : Google Scholar
25	Lee HT, Kim M, Kim JY, Brown KM, Ham A, D'Agati VD and Mori-Akiyama Y: Critical role of interleukin-17A in murine intestinal ischemia-reperfusion injury. Am J Physiol Gastrointest Liver Physiol. 304:G12–G25. 2013.PubMed/NCBI View Article : Google Scholar
26	Gulati N, Béguelin W and Giulino-Roth L: Enhancer of zeste homolog 2 (EZH2) inhibitors. Leuk Lymphoma. 59:1574–1585. 2018.PubMed/NCBI View Article : Google Scholar
27	Bai Y, Zhang Z, Cheng L, Wang R, Chen X, Kong Y, Feng F, Ahmad N, Li L and Liu X: Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer. J Biol Chem. 294:9911–9923. 2019.PubMed/NCBI View Article : Google Scholar
28	Jones BA, Varambally S and Arend RC: Histone methyltransferase EZH2: A therapeutic target for ovarian cancer. Mol Cancer Ther. 17:591–602. 2018.PubMed/NCBI View Article : Google Scholar
29	Pan YM, Wang CG, Zhu M, Xing R, Cui JT, Li WM, Yu DD, Wang SB, Zhu W, Ye YJ, et al: STAT3 signaling drives EZH2 transcriptional activation and mediates poor prognosis in gastric cancer. Mol Cancer. 15(79)2016.PubMed/NCBI View Article : Google Scholar
30	Yamagishi M and Uchimaru K: Targeting EZH2 in cancer therapy. Curr Opin Oncol. 29:375–381. 2017.PubMed/NCBI View Article : Google Scholar
31	Yong H, Wu G, Chen J, Liu X, Bai Y, Tang N, Liu L and Wei J: lncRNA MALAT1 accelerates skeletal muscle cell apoptosis and inflammatory response in sepsis by decreasing BRCA1 expression by recruiting EZH2. Mol Ther Nucleic Acids. 19:97–108. 2020.PubMed/NCBI View Article : Google Scholar
32	Zhao D, Li Z, Liu X, Liu N, Bao X, Sun H, Meng Q, Ren H, Bai J, Zhou X and Tang L: Lymphocyte expression of EZH2 is associated with mortality and secondary infectious complications in sepsis. Int Immunopharmacol. 89(107042)2020.PubMed/NCBI View Article : Google Scholar
33	Yong H, Wu G, Chen J, Liu X, Bai Y, Tang N, Liu L and Wei J: lncRNA MALAT1 accelerates skeletal muscle cell apoptosis and inflammatory response in sepsis by decreasing BRCA1 expression by recruiting EZH2. Mol Ther Nucleic Acids. 21:1120–1121. 2020.PubMed/NCBI View Article : Google Scholar
34	Yu Z, Rayile A, Zhang X, Li Y and Zhao Q: Ulinastatin protects against lipopolysaccharide-induced cardiac microvascular endothelial cell dysfunction via downregulation of lncRNA MALAT1 and EZH2 in sepsis. Int J Mol Med. 39:1269–1276. 2017.PubMed/NCBI View Article : Google Scholar
35	Wang Q, Xu L, Zhang X, Liu D and Wang R: GSK343, an inhibitor of EZH2, mitigates fibrosis and inflammation mediated by HIF-1α in human peritoneal mesothelial cells treated with high glucose. Eur J Pharmacol. 880(173076)2020.PubMed/NCBI View Article : Google Scholar
36	Liu Y, Peng J, Sun T, Li N, Zhang L, Ren J, Yuan H, Kan S, Pan Q, Li X, et al: Epithelial EZH2 serves as an epigenetic determinant in experimental colitis by inhibiting TNFα-mediated inflammation and apoptosis. Proc Natl Acad Sci USA. 114:E3796–E3805. 2017.PubMed/NCBI View Article : Google Scholar
37	Nakanishi Y, Reina-Campos M, Nakanishi N, Llado V, Elmen L, Peterson S, Campos A, De SK, Leitges M, Ikeuchi H, et al: Control of paneth cell fate, intestinal inflammation, and tumorigenesis by PKCλ/ι. Cell Rep. 16:3297–3310. 2016.PubMed/NCBI View Article : Google Scholar